Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents

Abstract

CDC25B, one of the three members of the CDC25 dual-specificity phosphatase family, plays a critical role in the control of the cell cycle and in the checkpoint response to DNA damage. CDC25B is responsible for the initial dephosphorylation and activation of the cyclin-dependent kinases, thus initiating the train of events leading to entry into mitosis.1 The critical role played by CDC25B is illustrated by the fact that it is specifically required for checkpoint recovery2, 3 and that unscheduled accumulation of CDC25B is responsible for illegitimate entry into mitosis.3-5 Here, we report that in p53-/- colon carcinoma cells, a moderate increase in the CDC25B level is sufficient to impair the DNA damage checkpoint, to increase spontaneous mutagenesis, and to sensitize cells to ionising radiation and genotoxic agents. Using a tumour cell spheroid assay as an alternative to animal studies, we demonstrate that the level of CDC25B expression modulates growth inhibition and apoptotic death. Since CDC25B overexpression has been observed in a significant number of human cancers, including colon carcinoma, and is often associated with high grade tumours and poor prognosis1, our work suggests that the expression level of CDC25B might be a potential key parameter of the cellular response to cancer therapy.